Microfluidic Immunoassay for Aβ Detection in Brain Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing intracellular Aβ species in human brain tissue lack the necessary spatial resolution and sensitivity, particularly for low-abundance proteins like Aβ oligomers, due to sample processing dilution and masking by high-abundance proteins, limiting the understanding of Alzheimer's disease pathogenesis.
Innovation Solution
A microfluidic immunoassay system combining laser capture microdissection (LCM) with matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, using a manifold with layered wells and anti-Aβ antibodies for immunocapture and subsequent MALDI analysis, allowing for the detection of Aβ monomers and oligomers with high sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If brain homogenates are used with immunoprecipitation and mass spectrometry analysis, then quantitative unbiased studies and biomolecule identification are enabled, but spatial resolution information is lost
Solution Approach 1:
The tissue sample is segmented into discrete regions of interest using laser capture microdissection, allowing spatially-resolved analysis of protein biomarkers while maintaining quantitative mass spectrometry capabilities for each segmented region
Solution Approach 2:
An indium-tin-oxide coated glass slide serves as an intermediary substrate that enables both the laser capture microdissection process and subsequent matrix-assisted laser desorption ionization mass spectrometry analysis, bridging the gap between spatial resolution and quantitative measurement
2Adaptability or versatility
If MALDI MS imaging is used for tissue protein profiling, then label-free detection and mapping of multiple analytes is achieved, but low abundant analytes are masked by highly abundant species
Solution Approach 1:
Specific regions containing cells of interest are extracted from the complex tissue matrix using laser capture microdissection, isolating the target analytes from the overwhelming background of highly abundant proteins that would otherwise mask low abundant species in bulk MALDI MS imaging
Solution Approach 2:
The analysis focuses on local regions of interest rather than the entire tissue sample, allowing low abundant analytes to be detected with sufficient signal-to-noise ratio by eliminating the masking effect of highly abundant proteins from other regions
3Measurement precision
If laser capture microdissection is used to selectively excise single cells, then spatial resolution is improved, but sample processing dilution and loss of precious minute analyte amounts occur
Solution Approach 1:
Multiple microdissected cells are collected and combined into a single pooled sample on the indium-tin-oxide coated glass slide, accumulating sufficient quantities of analyte for sensitive mass spectrometry detection while maintaining the spatial resolution benefit of selective cell isolation
Solution Approach 2:
The sample preparation transitions from three-dimensional tissue sections to a two-dimensional planar substrate, allowing efficient pooling of multiple cell samples in a concentrated format that minimizes analyte loss during processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the precise and sensitive identification of Aβ species, including monomers and oligomers, from small cell populations, overcoming the limitations of sample dilution and masking, thereby providing valuable insights into Alzheimer's disease mechanisms.
Implementation Method 1
laser capture microdissection (LCM)
Implementation Method 2
matrix-assisted laser desorption/ionization (MALDI) mass spectrometry
Implementation Method 3
introducing one or more anti-Aβ antibodies into the lower chamber of the layered well containing the cells in the upper chamber
Data Source
AI summary
Described herein are systems and methods for a microfluidic immunoassay for in situ mass spectrometry analysis of intracellular protein biomarkers in tissue. In some embodiments, the tissue may comprise human brain tissue. In some embodiments, the protein biomarkers may comprise Aβ species comprising monomers and oligomers of Aβ1-42, Aβ1-40, Aβ1-39, Aβ2-43, or combinations thereof. In some embodiments, the systems and methods may comprise laser capture microdissection (LCM) and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry.